These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38673831)

  • 1. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion.
    Deyev SM; Oroujeni M; Garousi J; Gräslund T; Li R; Rosly AHB; Orlova A; Konovalova E; Schulga A; Vorobyeva A; Tolmachev V
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.
    Goldstein R; Sosabowski J; Livanos M; Leyton J; Vigor K; Bhavsar G; Nagy-Davidescu G; Rashid M; Miranda E; Yeung J; Tolner B; Plückthun A; Mather S; Meyer T; Chester K
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):288-301. PubMed ID: 25391547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
    Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
    Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
    Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle.
    Garousi J; von Witting E; Borin J; Vorobyeva A; Altai M; Vorontsova O; Konijnenberg MW; Oroujeni M; Orlova A; Tolmachev V; Hober S
    Biomaterials; 2021 Jan; 266():120381. PubMed ID: 33120197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
    Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
    Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect Radioiodination of DARPin G3 Using N-succinimidyl-
    Vorobyeva A; Schulga A; Rinne SS; Günther T; Orlova A; Deyev S; Tolmachev V
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal composition and position of histidine-containing tags improves biodistribution of
    Vorobyeva A; Schulga A; Konovalova E; Güler R; Löfblom J; Sandström M; Garousi J; Chernov V; Bragina O; Orlova A; Tolmachev V; Deyev SM
    Sci Rep; 2019 Jun; 9(1):9405. PubMed ID: 31253840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.
    Deyev S; Vorobyeva A; Schulga A; Proshkina G; Güler R; Löfblom J; Mitran B; Garousi J; Altai M; Buijs J; Chernov V; Orlova A; Tolmachev V
    Mol Pharm; 2019 Mar; 16(3):995-1008. PubMed ID: 30608701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody
    Liu Y; Vorobyeva A; Xu T; Orlova A; Loftenius A; Bengtsson T; Jonasson P; Tolmachev V; Frejd FY
    Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34200197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sortase-Mediated Site-Specific Conjugation and
    Fay R; Törő I; Schinke AL; Simic B; Schaefer JV; Dreier B; Plückthun A; Holland JP
    Mol Pharm; 2022 Oct; 19(10):3576-3585. PubMed ID: 35434995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
    Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
    Contrast Media Mol Imaging; 2018; 2018():6930425. PubMed ID: 29977173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with
    Larkina M; Plotnikov E; Bezverkhniaia E; Shabanova Y; Tretyakova M; Yuldasheva F; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Garousi J; Gräslund T; Belousov M; Tolmachev V; Deyev S
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct In Vivo Comparison of
    Tolmachev V; Bodenko V; Oroujeni M; Deyev S; Konovalova E; Schulga A; Lindbo S; Hober S; Bragina O; Orlova A; Vorobyeva A
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells.
    Lan KH; Tsai CL; Chen YY; Lee TL; Pai CW; Chao Y; Lan KL
    Biochem Biophys Res Commun; 2021 Dec; 582():137-143. PubMed ID: 34710829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctional superparamagnetic nanoparticles conjugated with fluorescein-labeled designed ankyrin repeat protein as an efficient HER2-targeted probe in breast cancer.
    Li DL; Tan JE; Tian Y; Huang S; Sun PH; Wang M; Han YJ; Li HS; Wu HB; Zhang XM; Xu YK; Wang QS
    Biomaterials; 2017 Dec; 147():86-98. PubMed ID: 28938164
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.